Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
The University of Hong Kong
The University of Hong Kong
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)